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We would like to thank Pridmore and colleagues for their inter-
est in our recently published study showing that Motor Threshold
(MT) changed significantly on a daily basis during rTMS treatment
for depression [1]. Since MT is used to determine the appropriate
stimulation intensity for the rTMS treatment, we argue that such
variability raises concerns about the safety and efficacy of treat-
ment when MT is only measured at the start of therapy. In the
absence of randomized-control-trials that demonstrate the effects
of different MT determination frequencies on efficacy and side-
effects, we have suggested that the results of our study warrant
caution and more regular MT assessments. In the recent letter to
the editor by Pridmore and colleagues [2], the authors have argued
that such MT determination scheduling is unnecessary since, on
one hand, blinded clinical trials have shown clinical efficacy using
lower than 110e120% MT stimulation intensity ranges and, on the
other hand, MT and seizure threshold may not have a “fixed rela-
tionship”. We agree with Pridmore and colleagues, that the current
evidence in our study should not be regarded as definitive, as high-
lighted in our limitations section, since our study was not designed
to specifically understand if different MT assessment schedules
were associated with increase clinical response or risk of side ef-
fects. Nevertheless, such evidence is currently lacking and since
MT significantly varies across rTMS treatment, we believe the pre-
cautionary principle should prevail, and the data suggests at least
weekly MT measurements, as others did before [3].
In terms of efficacy from “underdosing”whenMT increases dur-
ing a course of therapy, while Pridmore and colleagues correctly
highlight the fact that successful treatment with rTMS has been
achieved with lower stimulation intensities, higher stimulation in-
tensities are more likely to elicit a neurophysiologic response [4]
and are also associated with higher clinical efficacy [5]. Such evi-
dence lead to the suggestion by TMS Clinical Consensus that stim-
ulation should be performed at 100e120% of MT in the context of
rTMS treatment for depression [6]. In terms of safety from “over-
dosing” with an increased risk of seizures, we agree that the rela-
tionship between MT and seizure threshold is still not fully
understood and other factors likely also contribute to seizure in-
ductionwith TMS. Nevertheless, particularly high rTMS stimulation
intensities can induce seizures and this is in fact the rationale
behind Magnetic Seizure Therapy, where convulsions are inten-
tionally elicited, similar to what is observed in electroconvulsive
therapy [7]. Furthermore, the safety parameters for TMS recognizeDOIs of original article: https://doi.org/10.1016/j.brs.2021.07.013, https://doi.org/
10.1016/j.brs.2021.08.013.
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1935-861X/© 2021 The Authors. Published by Elsevier Inc. This is an open access article uthe well-established relationship between TMS intensity and
seizure risk [8].
Finally, the present discussion raises another important ques-
tion: Is MT an adequate metric to define TMS treatment dose?
This is particularly challenged by the fact that MT is a neurophysi-
ologic measure acquired in brain motor regions, rather than the
dorsolateral prefrontal cortex (DLPFC), the actual rTMS treatment
target. Furthermore, a consistent relation between metrics of excit-
ability in motor cortex (including MT) and those in DLPFC has not
been shown. One potential solution that may be further explored
in future studies is to use a different electrophysiologic measure
in DLPFC to determine the stimulation intensity. A number of
TMS-EEGmeasures [9] are being explored and are theoretically bet-
ter proxies for safety and efficacy of stimulation in DLPFC. We
would like to thank Pridmore and colleagues for the opportunity
to further discuss the results of our study and their potential impact
in clinical practice. We are certain that such scientifically meaning-
ful debates help improve TMS field but most importantly patients’
quality of life.
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